Implications of Seizure-Cluster Treatment on Healthcare Utilization: Use of Approved Rescue Medications

References

• Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821–825. doi:10.15585/mmwr.mm6631a1
   PubMed Web of Science ®Google Scholar
• Moura L, Karakis I, Zack MM, Tian N, Kobau R, Howard D. Drivers of US health care spending for persons with seizures and/or epilepsies, 2010–2018. Epilepsia. 2022;63 (8) :2144–2154. doi:10.1111/epi.17305
   Web of Science ®Google Scholar
• Jafarpour S, Hirsch LJ, Gainza-Lein M, Kellinghaus C, Detyniecki K. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9–15. doi:10.1016/j.seizure.2018.05.013
   PubMed Web of Science ®Google Scholar
• Maglalang PD, Rautiola D, Siegel RA, et al. Rescue therapies for seizure emergencies: new modes of administration. Epilepsia. 2018;59(suppl 2):207–215. doi:10.1111/epi.14479
   PubMed Web of Science ®Google Scholar
• Fisher RS, Bartfeld E, Cramer JA. Use of an online epilepsy diary to characterize repetitive seizures. Epilepsy Behav. 2015;47:66–71. doi:10.1016/j.yebeh.2015.04.022
   PubMed Web of Science ®Google Scholar
• Penovich PE, Buelow J, Steinberg K, Sirven J, Wheless J. Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives. Neurologist. 2017;22(6):207–214. doi:10.1097/NRL.0000000000000140
   PubMed Web of Science ®Google Scholar
• Leguia MG, Andrzejak RG, Rummel C, et al. Seizure cycles in focal epilepsy. JAMA Neurol. 2021;78(4):454–463. doi:10.1001/jamaneurol.2020.5370
   PubMed Web of Science ®Google Scholar
• Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28(2):143–150. doi:10.1097/WCO.0000000000000177
   PubMed Web of Science ®Google Scholar
• Hogan RE, Gidal BE, Koplowitz B, Koplowitz LP, Lowenthal RE, Carrazana E. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61(3):455–464. doi:10.1111/epi.16449
   PubMed Web of Science ®Google Scholar
• Cloyd J, Haut S, Carrazana E, Rabinowicz AL. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62(4):846–856. doi:10.1111/epi.16847
   PubMed Web of Science ®Google Scholar
• Epilepsy Foundation. FDA news: Nayzilam (midazolam) nasal spray approved for seizure clusters. Available from: https://www.epilepsy.com/article/2019/5/fda-news-nayzilam-midazolam-nasal-spray-approved-seizure-clusters. Accessed March 16, 2021.
   Google Scholar
• Epilepsy Foundation. New drug: Valtoco (diazepam nasal spray) approved as rescue therapy for seizures. Available from: https://www.epilepsy.com/article/2020/1/new-drug-valtoco-diazepam-nasal-spray-approved-rescue-therapy-seizures. Accessed March 16, 2021.
   Google Scholar
• Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015;56(9):1376–1387. doi:10.1111/epi.13084
   PubMed Web of Science ®Google Scholar
• Cramer JA, Wang ZJ, Chang E, et al. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy Behav. 2014;31:356–362. doi:10.1016/j.yebeh.2013.09.046
   PubMed Web of Science ®Google Scholar
• Cramer JA, Wang ZJ, Chang E, et al. Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy Behav. 2014;32:135–141. doi:10.1016/j.yebeh.2014.01.016
   PubMed Web of Science ®Google Scholar
• Mitchell WG, Conry JA, Crumrine PK, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. North American Diastat Group. Epilepsia. 1999;40(11):1610–1617. doi:10.1111/j.1528-1157.1999.tb02047.x
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie, JE, Bossuyt, PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Wheless JW, Miller I, Hogan RE, et al. Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021;62(10):2485–2495. doi:10.1111/epi.17041
   PubMed Web of Science ®Google Scholar
• Wheless JW, Meng TC, Van Ess PJ, Detyniecki K, Sequeira DJ, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial. Epilepsia. 2019;60(9):1809–1819. doi:10.1111/epi.16300
   PubMed Web of Science ®Google Scholar
• Diastat® C-IV (diazepam rectal gel) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; 2021.
   Google Scholar
• NAYZILAM® (midazolam nasal spray) [prescribing information]. Smyrna, GA: UCB, Inc; 2021.
   Google Scholar
• VALTOCO® (diazepam nasal spray) [prescribing information]. San Diego, CA: Neurelis, Inc; 2022.
   Google Scholar
• Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105(3):362–367. doi:10.1016/j.eplepsyres.2013.02.018
   PubMed Web of Science ®Google Scholar
• Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338(26):1869–1875. doi:10.1056/NEJM199806253382602
   PubMed Web of Science ®Google Scholar
• Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–1808. doi:10.1111/epi.15159
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Clinical superiority findings. Available from: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings. Accessed June 23, 2020.
   Google Scholar
• Segal EB, Tarquinio D, Miller I, et al. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: an interim subgroup analysis from a phase 3, long-term, open-label safety study. Epilepsia. 2021;62(6):1442–1450. doi:10.1111/epi.16901
   PubMed Web of Science ®Google Scholar
• Sperling MR, Wheless JW, Hogan RE, et al. Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: results from a phase 3, open-label, repeat-dose safety study. Epilepsia. 2022;63(4):836–843. doi:10.1111/epi.17177
   Web of Science ®Google Scholar
• Cascino GD, Tarquinio D, Wheless JW, et al. Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: a population analysis. Epilepsia. 2022;63(7):1714–1723. doi:10.1111/epi.17249
   Web of Science ®Google Scholar
• Tarquinio D, Dlugos D, Wheless JW, Desai J, Carrazana E, Rabinowicz AL. Safety of diazepam nasal spray in children and adolescents with epilepsy: results from a long-term Phase 3 safety study. Pediatr Neurol. 2022;132:50–55. doi:10.1016/j.pediatrneurol.2022.04.011
   PubMed Web of Science ®Google Scholar
• Miller I, Wheless JW, Hogan RE, et al. Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: interim results from a phase 3, long-term, open-label, repeat-dose safety study. Epilepsia Open. 2021;6(3):504–512. doi:10.1002/epi4.12494
   PubMedGoogle Scholar
• Vazquez B, Wheless J, Desai J, Rabinowicz AL, Carrazana E. Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: interim results from a phase 3, open-label, 12-month repeat-dose safety study. Epilepsy Behav. 2021;118:107898. doi:10.1016/j.yebeh.2021.107898
   PubMed Web of Science ®Google Scholar
• Garnett WR, Barr WH, Edinboro LE, Karnes HT, Mesa M, Wannarka GL. Diazepam autoinjector intramuscular delivery system versus diazepam rectal gel: a pharmacokinetic comparison. Epilepsy Res. 2011;93(1):11–16. doi:10.1016/j.eplepsyres.2010.10.001
   PubMed Web of Science ®Google Scholar
• Penovich P, Wheless JW, Hogan RE, et al. Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021;121(Pt A):108013. doi:10.1016/j.yebeh.2021.108013
   PubMed Web of Science ®Google Scholar
• Higdon LM, Sperling MR. A review of a diazepam nasal spray for the treatment of acute seizure clusters and prolonged seizures. Expert Rev Neurother. 2021;21(11):1207–1212. doi:10.1080/14737175.2021.1965880
   PubMed Web of Science ®Google Scholar
• Hogan RE, Tarquinio D, Sperling MR, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: a Phase 1, open-label study. Epilepsia. 2020;61(5):935–943. doi:10.1111/epi.16506
   PubMed Web of Science ®Google Scholar
• Tanimoto S, Simons FE, Lockey R, Lieberman P, Kaliner M, Lowenthal R. A phase 1, five-period, five-treatment, randomized crossover study of the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine after administration of intranasal (IN) ARS-1 and intramuscular (IM) epinephrine to healthy volunteers. J Allergy Clin Immunol. 2020;145(2):AB77. doi:10.1016/j.jaci.2019.12.668
   Web of Science ®Google Scholar
• Rabinowicz AL, Carrazana E, Maggio ET. Improvement of intranasal drug delivery with Intravail® alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system. Drugs R D. 2021;21(4):361–369. doi:10.1007/s40268-021-00360-5
   Web of Science ®Google Scholar
• Buchhalter J, Shafer PO, Buelow JM, et al. Preferred practices for rescue treatment of seizure clusters: a consensus-driven, multi-stakeholder approach. Epilepsy Behav. 2021;117:107836. doi:10.1016/j.yebeh.2021.107836
   Web of Science ®Google Scholar
• Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1333–1348. doi:10.1111/epi.17237
   PubMed Web of Science ®Google Scholar